GlassScriptPhysician profile
Christina Shaw
NPI 1801044607
$2,262.11
in general payments reported to CMS, 2019-2025
22 companies · $575 in 2025
The $575 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $429 · 2022: $473 · 2023: $398 · 2024: $387 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $479.35 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $425.24 | 2021-2024 | |
| Novo Nordisk INC | $337.08 | 2021-2023 | Wegovy |
| Exact Sciences Corporation | $164.72 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $130.03 | 2025 | |
| Axsome Therapeutics, INC. | $121.82 | 2025 | Symbravo |
| Eisai INC. | $105.51 | 2024 | |
| Dexcom, INC. | $78.17 | 2021-2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $74.12 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Boston Scientific Corporation | $58.03 | 2025 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $43.63 | 2023-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $38.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.31 | 2021-2023 | Tradjenta |
| Merck Sharp & Dohme LLC | $24.83 | 2022 | |
| Amarin Pharma, INC. | $20.61 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.81 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.61 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $17.87 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.68 | 2024 | Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $15.38 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.